It is actually properly understood that IL-2 is usually a pleiotropic cytokine positioned on the crossroads of T mobile activation and regulation. As such, it is very important to engineer an IL-2 molecule that may be biased toward effector cells bearing the intermediate affinity receptor, like naïve and memory CD8+ T cells and NK cells, versus Tr